Nasdaq

Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.

Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...

Here’s what JP Morgan thinks about Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best High Volume Penny Stocks to Buy. On December 17, Priyanka ...

Forget Recursion Pharmaceuticals stock. This is a much better buy.

Eli Lilly is a safer way to capitalize on AI-driven drug discovery.
Ars Technica

Recursion or while loops: Which is better?

This Q&A is part of a weekly series of posts highlighting common questions encountered by technophiles and answered by users at Stack Exchange, a free, community-powered network of 100+ Q&A sites.
Seeking Alpha

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...
Seeking Alpha

Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns

Recursion Pharmaceuticals is a pioneer in AI-powered drug discovery but faces challenges in monetizing its innovations and aligning management's vision with sustainable revenue paths. The company's ...
Nasdaq

Recursion (RXRX) to Report Q2 Earnings: What's in the Cards?

We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...